-
公开(公告)号:US20130149281A1
公开(公告)日:2013-06-13
申请号:US13764509
申请日:2013-02-11
Applicant: NOVARTIS AG
Inventor: Trixi Brandl , Jiping Fu , Francois Lenoir , David Thomas Parker , Michael Patane , Branko Radetich , Prakash Raman , Pascal Rigollier , Mohindra Seepersaud , Oliver Simic , Aregahegn Yifru , Rui Zhang
CPC classification number: A61K38/07 , A61K38/00 , A61K38/06 , A61K45/06 , C07D209/96 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D487/10 , C07D491/20 , C07D495/10 , C07D498/04 , C07D498/10 , C07K5/06034 , C07K5/06078 , C07K5/06165 , C07K5/0808 , C07K5/0812 , C07K5/101 , C07K5/1016
Abstract: The present application describes a method of treating an HCV-associated disorder by administering to a subject in need thereof a pharmaceutically effective amount of a compound of formula I in combination with an additional HCV-modulating compound.
Abstract translation: 本申请描述了通过向有需要的受试者施用药学有效量的式I化合物与另外的HCV调节化合物组合来治疗HCV相关疾病的方法。
-
公开(公告)号:US12209144B2
公开(公告)日:2025-01-28
申请号:US17296679
申请日:2019-11-26
Applicant: Novartis AG
Inventor: Alec Nathanson Flyer , Andrei Alexandrovich Golosov , Philipp Grosche , Ian Lewis , Eugene Yuejin Liu , Andreas Marzinzik , Lauren Gilchrist Monovich , Johannes Ottl , Tajesh Jayprakash Patel , Patrick Crawford Reid , Mohindra Seepersaud
Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are described herein.
-